Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

NCT05165433 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Tumor
Metastatic Cancer

Interventions

BIOLOGICAL: NG-350A plus Pembrolizumab

Sponsor

Akamis Bio

Collaborators

[object Object]